There are currently 76 ongoing clinical trials involving Erectile Dysfunction
Of the 76 trials,27 trials are in Phase I
Furthermore, 25 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Erectile Dysfunction, a male health condition. The largest number of ongoing clinical trials for Erectile Dysfunction is conducted in Asia-Pacific. Europe and North America are among some of the other prominent regions engaged in Erectile Dysfunction-related drug trials.
Tasly Holding Group Co Ltd: The leading ongoing Erectile Dysfunction related clinical trial sponsor
Tasly Holding Group Co Ltd is the top sponsor for Erectile Dysfunction-related ongoing clinical trials.
Alter Laboratories, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmicell Co Ltd, Initiator Pharma AS, and Chinese Academy of Sciences are among other notable clinical trial sponsors involved in Erectile Dysfunction. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Erectile Dysfunction
Sildenafil Citrate (Viagra), Tadalafil (Cialis), and Sildenafil Citrate are key marketed drugs involving Erectile Dysfunction.
Sildenafil Citrate (Viagra) is an anti-erectile dysfunction agent. It functions via the Phosphodiesterase 5 Inhibitor mechanism of action It is formulated as tablets, film-coated tablets for oral route of administration. It is indicated for the treatment of erectile dysfunction. It is the first and the only FDA and European Union-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulation as a solution. Sildenafil Citrate was first approved in 1998 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Greenstone LLC and Viatris Inc.
Tadalafil (Cialis) is a benzodioxole derivative, acts as a vasodilator agent. It functions via the Phosphodiesterase 5 Inhibitor mechanism of action. It is formulated as film-coated tablets for the oral route of administration. Cialis is indicated for the treatment of erectile dysfunction (ED) and for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH). Tadalafil was first approved in 2002 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Eli Lilly and Co.
China
United States of America
Switzerland
United States of America
United States of America
Denmark
United States of America
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer